SFX by Ex Libris Inc.

Title:	Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Source:	Nature [0028-0836] Barbie, D A yr:2009

Basic

Full text

Full text available via Nature

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Scholl, C. "Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells." Cell 137.5 (2009): 821-834.
description	2.	Hahn, Cynthia K. "Proteomic and genetic approaches identify Syk as an AML target." Cancer cell 16.4 (2009): 281-294.
description	3.	Luo, J. "A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene." Cell 137.5 (2009): 835-848.
description	4.	Farmer, H. "Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy." Nature 434.7035 (2005): 917-21.
description	5.	Luo, J. "Principles of Cancer Therapy : Oncogene and Non-oncogene Addiction." Cell 136.5 (2009): 823-837.
description	6.	Bryant, Helen E. "Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase." Nature 447.7142 (2007): 346-7.
description	7.	Collier, Lara S S. "Transforming science: cancer gene identification." Current opinion in genetics & development 16.1: 23-9.
description	8.	Pagliarini, R. "Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure." EMBO reports 16.3 (2015): 280-296.
description	9.	Zhang, L. "Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis." Nature 464.7291 (2010): 1058-1061.
description	10.	Elledge, Stephen J. "Cancer Proliferation Gene Discovery Through Functional Genomics." Science 319.5863 (2008): 620-4.
description	11.	Bishop, J M M. "Molecular themes in oncogenesis." Cell 64.2 (1990): 235-48.
description	12.	Malumbres, M. "Cell cycle, CDKs and cancer: a changing paradigm." Nature reviews. Cancer 9.3 (2009): 153-66.
description	13.	Boss, D. "Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers." New England Journal of Medicine, The 361.2 (2009): 123-134.
description	14.	Tutt, A. "Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial." The Lancet 376.9737 (2010): 235-244.
description	15.	Rasouli-Nia, A. "Stable down-regulation of human polynucleotide kinase enhances spontaneous mutation frequency and sensitizes cells to genotoxic agents." Proceedings of the National Academy of Sciences of the United States of America 101.18 (2004): 6905-10.
description	16.	Iorns, E. "Utilizing RNA interference to enhance cancer drug discovery." Nature reviews. Drug discovery 6.7 (2007): 556-68.
description	17.	Bass, A. "SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas." Nature Genetics 41.11 (2009): 1238-1242.
description	18.	Stegmaier, K. "Genomic approaches to small molecule discovery." Leukemia 23.7 (2009): 1226-1235.
description	19.	Ebert, Benjamin L L. "Identification of RPS14 as a 5q- syndrome gene by RNA interference screen." Nature 451.7176 (2007): 335-9.
description	20.	Bender, A. "Use of a screen for synthetic lethal and multicopy suppressee mutants to identify two new genes involved in morphogenesis in Saccharomyces cerevisiae." Molecular and cellular biology 11.3 (1991): 1295-1305.